Clinical Trial Update: Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

View source ↗

Summary

Spesolimab post-marketing surveillance study in Korean patients with flares of generalized pustular psoriasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Status: WITHDRAWN